COMBINATIONS OF ANTITRANSFERRIN RECEPTOR MONOCLONAL-ANTIBODIES INHIBIT HUMAN TUMOR-CELL GROWTH-INVITRO AND INVIVO - EVIDENCE FOR SYNERGISTIC ANTIPROLIFERATIVE EFFECTS
- 1 October 1990
- journal article
- research article
- Vol. 50 (19) , 6295-6301
Abstract
Thirty-two murine monoclonal antibodies (MAbs) against the external domain of the human transferrin (Tf) receptor have been obtained using human Tf receptor glycoprotein produced in a baculovirus expression system as immunogen. The MAbs were tested separately, and in combination, for their ability to inhibit growth of CCRF-CEM leukemic T-cells in tissue culture. One MAb, D65.30, an IgG1, inhibited growth of CCRF-CEM cells as effectively as the anti-Tf receptor MAb 42/6, an IgA, previously found to have the highest antiproliferative activity in this assay. Some combinations of two or more MAbs inhibited the in vitro growth of CCRF-CEM much more effectively than single MAbs. Eleven IgG1 anti-Tf receptor MAbs, when combined individually with D65.30, increased the inhibition of CCRF-CEM growth from .apprx. 65% to < 90% in a 7-day growth assay. Similarly, many IgG MAbs in combination with 42/6 also inhibited CCRF-CEM growth by < 90%. The growth-inhibitory effects of certain combinations of MAbs were clearly synergistic, because either one or both MAbs tested separately were inactive. These pairs of MAbs also inhibited the growth of HL-60 and KG-1 leukemic cells by < 90% and partially inhibited the growth of K562 erythroleukemia and M21 melanoma cells, which are resistant to MAb 42/6. However, not all combinations of anti-Tf receptor MAbs were more effective; eight MAbs markedly antagonized the antiproliferative effects of D65.30, whereas 12 others had little or no effect. Preincubation of HL-60 cells with three different pairs of MAbs, D65.30 and A27.15, B3/25 and 42/6, and B3/25 and TR3A, inhibited subsequent colony formation by < 95%, demonstrating that their action is cytotoxic, not cytostatic. The antiproliferative activity of these pairs of MAbs correlates with their ability to block Tf-mediated 59Fe uptake and perturb Tf receptor expression. Treatment of nude mice bearing established s.c. CCRF-CEM tumors with a combination of MAbs D65.30 and A27.15 inhibited tumor growth and in some animals led to complete tumor regression. Each MAb administered separately was much less effective. We conclude that combinations of two or more anti-Tf receptor MAbs can interact synergistically to inhibit cell growth in vitro and tumor growth in vivo.This publication has 28 references indexed in Scilit:
- Role of transferrin, Fe, and transferrin receptors in myeloid leukemia cell growth. Studies with an antitransferrin receptor monoclonal antibody.Journal of Clinical Investigation, 1985
- Selection of cell lines resistant to anti-transferrin receptor antibody: evidence for a mutation in transferrin receptor.Molecular and Cellular Biology, 1984
- Expression of transferrin receptor on murine hematopoietic progenitorsCellular Immunology, 1984
- Effects of anti‐transferrin receptor antibodies on growth of normal and malignant myeloid cellsInternational Journal of Cancer, 1983
- The mechanism of synergistic complement‐mediated lysis of rat red cells by monoclonal IgG antibodiesEuropean Journal of Immunology, 1983
- Murine cell surface transferrin receptor: Studies with an anti‐receptor monoclonal antibodyJournal of Cellular Physiology, 1982
- Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro.Proceedings of the National Academy of Sciences, 1982
- Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin.Proceedings of the National Academy of Sciences, 1981
- Properties of a baboon lymphotropic herpesvirus related to Epstein‐Barr virusInternational Journal of Cancer, 1976
- ENZYME IMMUNOASSAYS IN DIAGNOSTIC MEDICINE - THEORY AND PRACTICE1976